A Comparison of 2-Year Outcomes in ZUMA-1 (Axicabtagene Ciloleucel [Axi-Cel]) and SCHOLAR-1 in Patients (Pts) with Refractory Large B Cell Lymphoma (LBCL) Neelapu, S. S., Locke, F. L., Bartlett, N. L., Lekakis, L. J., Reagan, P. M., Miklos, D. B., Jacobson, C. A., Braunschweig, I., Oluwole, O. O., Siddiqi, T., Lin, Y., Crump, M., Kuruvilla, J., Van Den Neste, E., Farooq, U., Navale, L., DePuy, V., Kim, J. J., Gisselbrecht, C. ELSEVIER SCIENCE INC. 2020: S232

View details for Web of Science ID 000516887900345